Af­ter build­ing pipelines from Glax­o­SmithK­line to Flag­ship, Paul Pe­ter Tak takes the helm at an un­der-the-radar on­colyt­ic virus play­er

Paul Pe­ter Tak has done it all: From a pro­fes­sor­ship in his na­tive Nether­lands to the head of im­munoin­flam­ma­tion R&D at Glax­o­SmithK­line, from lead­ing small biotechs to more re­cent­ly join­ing the ven­ture world as a Flag­ship part­ner, he’s of­ten found him­self in roles he wouldn’t have imag­ined him­self.

His lat­est ap­point­ment as CEO of on­colyt­ic virus com­pa­ny Can­del Ther­a­peu­tics is one of them.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER